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Abstract: Bone marrow Mesenchymal Stem Cells (BM-MSCs), due to their strong protective and
anti-inflammatory abilities, have been widely investigated in the context of several diseases for
their possible therapeutic role, based on the release of a highly proactive secretome composed of
soluble factors and Extracellular Vesicles (EVs). BM-MSC-EVs, in particular, convey many of the
beneficial features of parental cells, including direct and indirect β-amyloid degrading-activities,
immunoregulatory and neurotrophic abilities. Therefore, EVs represent an extremely attractive
tool for therapeutic purposes in neurodegenerative diseases, including Alzheimer’s disease (AD).
We examined the therapeutic potential of BM-MSC-EVs injected intracerebrally into the neocortex of
APPswe/PS1dE9 AD mice at 3 and 5 months of age, a time window in which the cognitive behavioral
phenotype is not yet detectable or has just started to appear. We demonstrate that BM-MSC-EVs are
effective at reducing the Aβ plaque burden and the amount of dystrophic neurites in both the cortex
and hippocampus. The presence of Neprilysin on BM-MSC-EVs, opens the possibility of a direct
β-amyloid degrading action. Our results indicate a potential role for BM-MSC-EVs already in the
early stages of AD, suggesting the possibility of intervening before overt clinical manifestations.
Keywords: bone marrow mesenchymal stem cells; extracellular vesicles; Alzheimer’s disease;
APPswe/PS1dE9 AD mice; Neprilysin; dystrophic neuritis; SMI; Aβ plaques
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1. Introduction
Alzheimer’s disease (AD), the leading cause of dementia, has recently been attracting a lot of
attention from the scientific community, since millions of people are affected by this incurable pathology;
furthermore, the number of patients is destined to increase in the coming decades [1]. The limited
knowledge of the etiology of Alzheimer’s has rendered in vain numerous attempts hitherto pursued
to find a resolutive treatment that is not simply limited to the alleviation of symptoms. Therefore,
a worldwide effort is underway to discover the mechanisms responsible for the disease onset and
progression and to find an efficacious therapy, developing either novel treatments [2–4] or preventive
strategies [5].
Cell therapy is becoming a new reality for many diseases. Due to the plasticity and multifaceted
features of stem cells, recent studies have also focused on their possible exploitation in AD [6–8].
Multipotent bone marrow mesenchymal stem cells (BM-MSCs) represent a heterogeneous subset of
stromal cells. They can be isolated from bone marrow or many other adult tissues, including periosteum,
trabecular bone, adipose tissue, synovium, pancreas, placenta and cord blood [9]. They typically give
rise to cells of diverse lineages, including adipocytes, chondrocytes and osteocytes. In recent years,
BM-MSCs have been shown to be endowed with immunoregulatory abilities [10]. This property makes
them suitable as possible therapeutic tools for AD [11], a disease characterized by a large inflammatory
component mediated by microglia activation [2]. Interestingly, transplantation of human adipose
tissue-derived MSCs (ADSC) into the brain has been shown to reduce Aβ deposition and to restore
microglial function in transgenic APPswe/PS1dE9 (APP/PS1) mice, a preclinical model widely used
for the study of AD [12]. Moreover, BM-MSCs alleviated memory deficits in AD mice by modulating
immune responses [13].
More recently the discovery of Extracellular Vesicles (EVs) originating from MSCs, retaining
most of the properties of the cells of origin, is leading scientists to develop cell-free therapies to limit
the potential side effects associated with the use of stem cells [14], including induction of vascular
obstruction [15], lung retention after transplantation (resulting in a reduction in the population
of cells that reach the target site) [16], the production of allo-antibodies was observed following
repeated administration of MSCs [17], as well as a controversial protumorigenic effect [18]. In in vitro
experiments, exosomes from human ADSC significantly decreased both secreted and intracellular
Aβ levels in N2a cells engineered to overexpress human APP, by virtue of the proteolytic activity
of neutral endopeptidase Neprilysin (NEP), the dominant Aβ peptide-degrading enzyme in the
brain, towards Aβ1-42 peptide [19]. Human ADSC derived EVs were thus envisaged to represent
a therapeutic tool based on their Aβ-degrading ability [19]. Another therapeutic perspective put
forward is a possible role of EVs in Aβ1-42 scavenging, thanks to the ability of EVs glycosphingolipids
to bind to Aβ and to convey it to the microglia for phagocytosis [20]. In addition, MSC-EVs have been
described to exert an antiapoptotic, neuroprotective role [21,22] and to promote neurite outgrowth
and axon regeneration of injured neurons [23,24]. Therefore, MSC-EVs, similarly to parental cells,
are endowed with anti-inflammatory, amyloid-β degrading and neurotrophic activities that could
stimulate neighboring parenchymal cells to start repairing damaged tissues. These properties have been
considered very interesting to test in in vivo models of AD (for a recent review, see [11]). Altogether,
this evidence suggests that MSC-derived EVs might play a therapeutic effect in AD.
Despite the massive investments in AD drugs, the disappointing failure of several clinical trials
conducted in recent years is forcing the neuroscience community to orient itself towards initiating the
treatments at earlier stages of the pathology. Indeed, the pathophysiological process of AD is known to
begin decades before diagnosis, with amyloid buildup occurring when only subtle clinical symptoms,
if any at all, are evident [25].
In the present study, we hypothesized that the early therapeutic exploitation of MSC-EVs could be
efficacious in addressing some of the disease features of AD, which may possibly slow, or even prevent,
manifestation of the pathological signs. For this purpose, bone marrow mouse MSC-EVs were injected
into the neocortex of APP/PS1 mice at two different time points: 5 months, when amyloid plaques were
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definitely present, and 3 months, when they were instead just starting to appear. Our results indicate
that an early intervention with BM-MSC-EVs reduces pathological signatures of AD, thus suggesting
that MSC-EVs could be regarded as a potentially effective treatment for the disease.
2. Materials and Methods
2.1. Culture of Purified Murine Bone Marrow Mesenchymal Stem Cells
Primary Bone Marrow Mesenchymal Stem Cells (BM-MSCs) were prepared from 4–12 week-old
C57BL/6 mice by flushing femur and tibia bones cavities using plain culture medium, removing red
blood cells by lysis with 0.84% (w/v) NH4Cl solution for 5 min at RT, then filtering through a 70 µm
filter mesh and seeding them in tissue culture flasks in αMEM supplemented with 20% (v/v) FBS
(HyClone, Cat.N. SH30070.03, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) in a 5% CO2 incubator.
Nonadherent cells were removed 48 hours later by changing the medium. Cells were passaged at
sub-confluency (~80%) with a split ratio of 1:3, or cryopreserved and stored at −80 ◦C in 10% DMSO in
FBS. BM-MSCs were used from passages 9 to 14 (P9–P14).
2.2. BM-MSC Osteogenic and Adipogenic Lineage Differentiation Assay
Differentiation of murine BM-MSCs towards the osteogenic and adipogenic lineages was performed
in 6-well plates (5 × 103 cells/well) with osteogenic differentiation medium (αMEM with 5% FBS,
dexamethasone 10 nM, ascorbic acid 0.3 M, β-glycerophosphate 10 mM), adipogenic differentiation
medium (αMEM with 5% FBS, dexamethasone 10 nM and insulin 0.5 µg/mL) or control medium
(αMEM with 5% FBS). After 30 days, osteogenic and adipogenic differentiation were revealed by
Alizarin Red and Red Oil O staining, respectively.
2.3. Senescence Associated β-Galactosidase (SA-β-Gal) Assay
For SA-β-Galactosidase staining cells were washed in PBS and fixed in 2% (w/v) formaldehyde,
0.2% (w/v) glutaraldehyde for 5 min at RT and after 1 wash in PBS were incubated O/N in freshly prepared
staining solution at pH 6.0 containing 1mg/mL Xgal (5-bromo-4-chloro-3-indolyl-β-galactopyranoside,
Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany) in 8 mM citric acid/sodium phosphate buffer,
150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferrocyanide and 5 mM potassium ferricyanide.
Cell nuclei were counterstained with Hoechst 33342 and visualized with a 20× objective on a wide field
system (Olympus CellˆR system with an IX81 inverted microscope, Olympus, Hamburg, Germany)
equipped with an MT20 illumination device with fluorescent filters (Ex: 361 nm; Em: 486 nm) and
Differential Interference Contrast (DIC). For each condition, a minimum of 6 fields (containing on
average of 50 cells) were acquired (Olympus Xcellence 1.2 RealTime controller software), and the
percentage of β-Gal positive cells on the total number of cells was calculated after manually counting
with Fiji ImageJ software the β-Gal positive cells that appeared with a black cytoplasm (DIC channel)
and the Hoechst positive nuclei (Hoechst channel). The percentage of β-Gal positive cells on the total
number of cells was plotted and subjected to statistical analysis with Graphpad Prism v.7.0 software.
2.4. Flow Cytometry Profiling of BM-MSCs
Cells were stained using the appropriate saturating concentrations of the following
conjugated antibodies: FITC-conjugated mouse hematopoietic lineage Cocktail (Lin, eBioscience™,
San Diego, CA, USA), rat anti-mouse CD31 Brilliant-Violet™510-conjugated, rat anti-mouse Ly
6A/E (Sca1) phycoerythrin-conjugated, hamster anti-rat/mouse CD49a Alexa-Fluor®647-conjugated
(BD Biosciences, San Jose, CA, USA), rat anti-mouse CD9 FITC-conjugated, rat anti-mouse/human
CD44 Alexa-Fluor®647-conjugated, Armenian hamster anti-mouse/rat CD29 Pacific Blue™ conjugated,
rat anti-mouse CD73 Alexa-Fluor®647-conjugated, rat anti-mouse CD105 PE/Cy7™-conjugated,
rat anti-mouse CD117 (c-kit) PerCP™/Cy5.5-conjugated (BioLegend®, San Diego, CA, USA). Following
surface staining, cells were fixed using 2% (w/v) paraformaldehyde (PFA) in PBS for 20 min on ice.
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An LSR Fortessa analyzer (BD Biosciences, San Jose, CA, USA), equipped with 4 lasers and able to
discriminate up to 18 fluorophores, was used for sample acquisition. Instrument performance was
checked daily using CS&T Beads (BD Biosciences, San Jose, CA, USA) and SPHERO Rainbow beads
(Spherotech, Lake Forest, IL, USA). Data acquisition and analysis were performed with FACSDiva v.6.2
(BD Biosciences, San Jose, CA, USA) and Flow-Jo v.9.7 (Tree Star Inc., Ashland, OR, USA), respectively.
2.5. Isolation of BM-MSC-Derived EVs
EVs were obtained from BM-MSC supernatants by a protocol adapted from [26], whereby
a monolayer of approx. 3 × 106 murine BM-MSCs, seeded in tissue culture flasks, was washed three
times with PBS and incubated in serum-free αMEM for 3 h to induce EV release. The culture medium
was then collected and centrifuged at 4 ◦C, first at 300 g for 10 min to discard dead cells, then at 1000× g
for 20 min to eliminate cellular debris, and finally for 90 min at 110,000 g to pellet EVs composed of
Exosomes and Microvesicles. For in vivo studies following removal of the centrifugation supernatant,
EVs were rinsed in PBS and ultracentrifuged again before use. EV-enriched pellets were resuspended
in PBS. For biochemical studies, EVs were solubilized in lysis buffer (10 mM HEPES-NaOH pH 7.5;
2 mM EDTA pH 8.0; 1% (w/v) SDS; supplemented with protease and phosphatase inhibitors) and
protein content was quantified by micro-BCA assay (Thermo Fisher Scientific, Waltham, MA, USA).
2.6. BM-MSC-EV Characterization with Nanoparticle Tracking Analysis (NTA)
NTA measurements were performed with NanoSight NS300 (Malvern Panalytical, Malvern, UK)
for determination of the size and concentration of isolated EV samples. Diluted samples (1:6 in 500 µL
of PBS) were injected into the sample chamber with sterile syringes (BD Plastipak Insulin syringe,
Franklin Lakes, NJ, USA) until the liquid reached the tip of the nozzle. All measurements were
performed in dynamic mode, with syringe pump infusion rate 30, at room temperature and with the
same viscosity value. EV samples and the EV-depleted media were analyzed right after isolation with
manual shutter and gain adjustments. NTA 3.3 Dev Build 3.3.301 software was used for recordings,
measurements and data output collection. Five dynamic measurements of each sample were performed
(60 s each). Scripts were run via SOP-type procedures with default options for standard measurements.
For each polydisperse sample, the average FTLA (particles/frame against size distribution) was
considered. Raw particles size and concentration data were plotted and subjected to statistical analysis
with GraphPad Prism 6.0® or 7.0® software.
2.7. BM-MSC EV Profiling by Flow Cytometry
To limit background noise from dust and salt crystals, 0.22-µm-filtered sheath fluid was used for
sample acquisition. The FSC and SSC gate for identifying EVs was determined by using dimensional
beads (size range: 0.1–0.9µm, Biocytex, Marseille, France; and 0.79–1.34µm, Spherotech Inc. Lake Forest,
IL, USA). Only events smaller than 0.9 µm were included in the analysis gate. Cell membrane fragments
stained using phalloidin-TRITC (Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany) at 4 ◦C for
30 min, in the dark, were excluded from the analysis gate for detection of MSC-EVs. EVs were stained
using the appropriate saturating concentrations of conjugated monoclonal antibodies anti-CD9-FITC
and anti-CD49-A647 in filtered PBS for 20 min at 4 ◦C. Staining specificity was further confirmed by
subjecting stained EVs following acquisition to 0.05% (w/v) TX-100 solubilization and reacquiring
the sample afterwards. All gated regions were defined using the appropriate fluorescence minus-one
(FMO) controls. Fluidic stability, laser alignment, and time delay were checked daily to minimize
fluctuations in the fluorescent signal recovered. FACS Canto II analyzer (BD Biosciences, San Jose,
CA, USA) equipped with 3 lasers able to discriminate up to 10 fluorophores was used for sample
acquisition. Instrument performance was checked daily using CS&T Beads (BD Bioscience, San Jose,
CA, USA) and SPHERO Rainbow beads (Spherotech, Lake Forest, IL, USA). Prior to the acquisition
of the EV sample, the instrument was cleaned by washing more than 10 times with Clean FACS
buffer (BD Biosciences, San Jose, CA, USA) and water in turn, for 10 min each at a high flow rate.
Cells 2019, 8, 1059 5 of 20
The instrument data acquisition and analysis were performed with FACSDiva v.6.2 (BD Pharmingen)
and Flow-Jo v.9.7 (Tree Star Inc., Ashland, OR, USA), respectively.
2.8. Cryo-Electron Microscopy of BM-MSC EVs
Right after preparation of EVs by centrifugation, a 3.5-µL droplet of EVs freshly resuspended in
PBS at a final concentration of 0.2 × 109 particles/µL was applied on a copper 300-mesh Quantifoil
R2/1 holey carbon grid, previously glow discharged for 30 seconds at 30 mA using a GloQube system
(Quorum Technologies, Laughton, UK). After an incubation of 60 seconds, the grid was plunge-frozen
in liquid ethane using a Vitrobot Mk IV (Thermo Fisher Scientific, Waltham, MA, USA) operating at
4 ◦C and 100% RH. Images of the vitrified specimens were acquired using a Talos Arctica transmission
electron microscope operating at 200 kV and equipped with a CETA 16M (all from Thermo Fisher
Scientific, Waltham, MA, USA) camera. Images with applied defocus values between 3 and 5 µm were
acquired with a total exposure time of 2 seconds and a total accumulated dose of 95 electrons per
A2 at nominal magnifications of 22,000× or 45,000×, corresponding to a pixel size of 4.7 Å/pixel and
2.3 Å/pixel at the specimen level, respectively.
2.9. Western Blotting of BM-MSC Cell and EV Lysates
Western blots of BM-MSC lysates (lysis buffer: 10mM HEPES-NaOH pH 7.5; 2mM EDTA pH8.0;
1% (w/v) SDS; supplemented with protease and phosphatase inhibitors) at different passages and
of EVs at passage 14 were prepared and after addition of Laemmli loading buffer were denatured
(10 min at 65 ◦C) and loaded onto 4–15% Criterion™ TGX Stain-Free™ (Bio-Rad, Hercules, CA, USA)
for SDS-PAGE. The proteins were transferred to nitrocellulose membranes using the Trans Blot® Turbo
System™ (Bio-Rad, Hercules, CA, USA).
Membranes were cut according to molecular weight standards in order to maximize incubation
with different antibodies and were allowed to react with antibodies directed against the following
proteins: Histone H2A.X phospho S139 (1:50000; Abcam, Cambridge, UK), p16INK4a (1:1000; Santa Cruz,
Dallas, TX, USA), Neprilysin (1:1000; Merck-Millipore, Burlington, MA, USA), AGO-2 (1:1000;
Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany), Alix (1:1000; Cell Signaling, Danvers MA, USA),
CD9 (1:500; Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany), TSG101 (1:1000; Sigma-Aldrich®,
Merck KGaA, Darmstadt, Germany), CD63 (1:500; Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany
& Santa Cruz, Dallas, TX, USA) and HSP70 (1:5000; Sigma-Aldrich®, Merck KGaA, Darmstadt,
Germany), in 5% (w/v) BSA (Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany) or skimmed
milk (Régilait, Saint-Martine-Belle-Roche, France) in TBS-T (137 mM NaCl, 20 mM Tris-HCl pH 7.5.,
0.1% (v/v) Tween-20). Bands of interest were revealed following incubation with goat anti-rabbit,
anti-mouse and anti-Armenian hamster secondary antibodies conjugated with HRP and revealed by
SuperSignal™ West Pico PLUS or Femto (Thermo Scientific™, Thermo Fisher Scientific, Waltham,
MA, USA). Acquisition of chemiluminescence signals was performed with a ChemiDoc MP system
(Bio-Rad, Hercules, CA, USA). Normalization of Western blot signals was performed on the total
protein loaded on each lane by the Stain-Free™ technology using the Image Lab™ v.6.0 (Bio-Rad,
Hercules, CA, USA) software as previously described [27].
2.10. Quantitative RT-PCR
BM-MSC P14 and primary murine Fibroblasts, prepared from the skin of 3-day-old pups
according to previously described protocols [28,29], were solubilized in 500 µL of TRI Reagent®
solution (ZYMO RESEARCH, Irvine, CA, USA) for RNA extraction. Total RNA was isolated using
the RNA Direct-zol™ MiniPrep Isolation Kit (ZYMO RESEARCH, Irvine, CA, USA) according to
the manufacturer’s protocol. After elution in 25 µL DNase/RNAse-free water, the total RNA was
quantified using NANOdrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA)
and its quality checked for by 260/280 nm optical density ratio. 1 µg of RNA underwent reverse
transcription with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems™, Thermo
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Fisher Scientific, Waltham, MA, USA). Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed in a final volume of 10 µL by means of a Sybr Green detection kit (SensiFAST™ SYBR®
Lo-ROX, Bioline, Paris, France) in a Viia7 Real-Time PCR System (Applied Biosystems™, Thermo Fisher
Scientific, Waltham, MA, USA). Each transcript was evaluated with at least duplicate measurements
and Neprilysin relative expression was calculated following normalization against that of β-actin with
the comparative ∆∆CT method using the values obtained from skin fibroblasts mRNA as a reference.
The following primers were used: Neprilysin Forward: 5’-CCCAGTGTATGGTATACCAG-3’; Reverse:
5’-TGGCCAATACCTCCATTATCA-3’; β-actin Forward: 5’-GCCATCCTGCGTTCTGGA-3’, Reverse:
5’-GCTCTTCTCCAGGGAGGA-3’.
2.11. Animal Studies
Procedures involving animal handling and care were performed in accordance with protocols
approved by the Humanitas Clinical and Research Center (Rozzano, Milan, Italy) in compliance with
national (4D.L. N.116, G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council
Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National Institutes of Health Guide for the Care
and Use of Laboratory Animals, US National Research Council, 2011). All efforts were made to
minimize the number of mice used and their suffering. For in vivo experiments, 5–6 animals per
experimental condition were used of the double transgenic Alzheimer’s Disease mouse model APP/PS1
(APPswe-PS1dE9) purchased from Jackson Laboratory [30] (Bar Harbor, ME, USA). Animals were
housed and bred in the SPF animal facility of Humanitas Clinical and Research Center. BM-MSC-EVs
were resuspended in PBS before intracranial injection into male APP/PS1 mice. The head skin of
anesthetized animals (100 mg/kg ketamine/10 mg/kg xylazine) was incised with a scalpel and the skull
exposed. The skull surface and the bregma served as the stereotaxic zero points. The cranium was
perforated at two sites (AP 1 mm, ML 2 mm, DV 2 mm), once in each hemisphere, and using a Hamilton
precision syringe (26G needle), 4 µL of BM-MSC-derived EV suspension (5.6 µg/µL, corresponding
to 22.4 µg of MSC-EVs obtained from ~3x106 cells corresponding ~1 × 109 particles) or 4 µL of PBS
was injected into the neocortex as previously described [31]. Twenty-five days after treatment, animals
were sacrificed according to the approved animal protocol guidelines and intracardially perfused with
4% (w/v) PFA.
2.12. Immuno-Histochemical and Immunofluorescence Staining
Brains of perfused animals, after further ON fixation in 4% (w/v) PFA, were washed with PBS and
freshly cut by vibratome (Leica VT1000-S vibroslicer). 30 µm thick para-sagittal sections were stored in
anti-freezing solution (v/v: 3% glycerol, 3% Ethylene glycol, 40 mM phosphate buffer, pH 7.4) at −20 ◦C,
following cryopreservation in 7% (w/v) and 20% (w/v) sucrose solutions (in 0.1M Phosphate Buffer,
pH: 7.4), until use. For immunohistochemical staining, free-floating slices were permeabilized in PBS
solution (PBS, 3% (v/v) Methanol, 0.1% (w/v) Triton X-100) and treated with 3% (v/v) Hydrogen Peroxide.
For antigen retrieval, slices were treated with 90% (v/v) formic acid in water. Slices were subsequently
washed with 0.1% (w/v) Triton X-100 in PBS and incubated for 1 h at RT in blocking solution (10% (v/v)
horse serum, 0.1% (w/v) Triton-X100 in PBS). All slices were stained O/N at 4 ◦C with 6E10 antibody
(β-amyloid, 1-16 Monoclonal Antibody, Covance®, BioLegend®, San Diego, CA, USA) in blocking
solution. The immuno-detection was performed with an anti-mouse secondary antibody followed by
MAC1 Mouse Probe and MAC1 Universal HRP-Polymer (Biocare Medical, Pacheco, CA, USA) and
DAB (3’DiAminoBenzidine; Biocare Medical, Pacheco, CA, USA) revelation. Slices were mounted on
glass slides with FluorSave™ Reagent (Calbiochem®, Merck KGaA, Darmstadt, Germany).
For immunofluorescence staining, brain sections were incubated for 10 min in 0.04% (w/v) ThT
(Sigma-Aldrich®, Merck KGaA, Darmstadt, Germany) solution, then washed for 1 minute with
80% (v/v) methanol in water and stained O/N at 4 ◦C with Iba1 (rabbit anti-mouse, FUJIFILM Wako
Chemicals Europe GmbH, Neuss, Germany) and Smi31 and Smi32 monoclonal anti-mouse antibodies
(BioLegend®, San Diego, CA, USA). After washing, the secondary antibodies (anti-rabbit secondary
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antibody conjugated with Alexa 488 and anti-mouse secondary antibody conjugated with Alexa
633 fluorochromes) were incubated for 1h at RT in blocking solution. Slices were mounted on glass
slides and mounted with FluorSave™ Reagent (Calbiochem®, Merck KGaA, Darmstadt, Germany).
2.13. Image Acquisitions and Analysis
Immuno-histochemically stained slices were acquired by Olympus DotSlide microscope with
a 10× objective, connected to a computer equipped with OlyVIA® 2.9 viewer software (Olympus,
Hamburg, Germany). Quantification of β-amyloid plaques on immuno-histochemically stained brain
slices of APP/PS1 mice was performed using ImageJ software. Four parameters were evaluated
to describe plaques: Area Mean (µm2), Plaque Solidity (a.u.), i.e., β-amyloid intensity within
immune-revealed plaques and calculated as [Area]/[Convex area], and Plaque Density (n plaques/ µm2
slice area). About 10 slices for each APP/PS1 animal injected with PBS or EVs were analyzed. Within
each slice, two areas of interest were manually selected: the cortex and the hippocampus. Within these
areas, the total number of plaques was counted. An arbitrary threshold has been fixed and maintained
for the whole analysis of slices of the same experimental group. Collected data were averaged and
analyzed with Graph Pad Prism6® software. All values were expressed as the mean ± SEM. Graphs
represent the average of plaques area (Area, µm2), solidity (a.u.) and of plaque density (n/µm2) for all
analyzed animals (5–6 animals per group).
Confocal images were acquired using a Leica TCS SP5 confocal microscope equipped with a HCX
PL APO lambda blue 63x/1.4 OIL objective. ThT signal was revealed by exciting with 405 nm, Iba1 with
488 nm and Smi31-32 with 633 nm lasers. Voxel size was established using Nyquist criteria. Confocal
images were analyzed by IMARIS v7.4.2 software (Oxford Instruments, Abingdon-on-Thames, UK).
Briefly, 3D image reconstruction of Z-planes of ThT and Smi31-32 signals was performed and spots
of Smi31-32 signal were quantified using the IMARIS software function “Spot” with the following
parameters: detected spot number/estimated diameter = 0.962 µm; Background Subtraction Quality
between 40 and 200. Spot detection was monitored and corrected manually, setting 90 µm as the
minimum spot to be considered as a bona fide Smi31-32 signal. The ThT signal volume was quantified
by the “Surface” function, setting Smooth as 0.192, Absolute Intensity, Threshold between 140 and 75.
Smi31-32 ROI volume analysis was drawn according to the Iba1 (to detect microglia cells around the
plaques) fluorescence around the ThT signal. Smi31-32 spot density was estimated with the following
formula: Ratio of [Smi31-32 spots / (Iba1 ROI volume minus ThT volume)].
2.14. Statistical Analysis
Average values obtained from plaques quantifications of EVs treated versus non-treated APP/PS1
animals were compared using the unpaired non-parametric Mann-Whitney test, with Prism6®
software. In general, the one tail hypothesis was chosen (reduction of all parameters tested) with
Welch’s correction. All data are expressed as means ± SEM. p-Values lower than 0.05 were considered
statistically significant. In the graphs, one * corresponds to p < 0.05, two ** corresponds to p < 0.01.
3. Results
EVs derived from mouse BM-MSCs were investigated for a possible therapeutic effect in APP/PS1
mice. To this end, MSCs were prepared from adult bone marrow and characterized for typical markers,
following criteria suggested by the International Society for Cellular Therapy [32], including evaluating
their ability to differentiate towards osteogenic and adipogenic lineages.
The flow cytometry characterization shows that BM-MSCs express stemness markers, such as
SCA1, along with CD73 and CD105, specific markers for the mesenchymal origin of cells. BM-MSCs
were also positive for markers expected to be present on the surface of EVs, such as CD44, CD29,
CD49 and CD9 [11]. Lineage Hematopoietic Markers (LIN), CD117 and CD31, were not detected,
excluding the contamination of cell cultures by hematopoietic cells or their precursors (Figure 1a).
Reliability of BM-MSC preparations was confirmed by the repeatability of the staining for the different
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markers in 6 independent preparations (Figure 1b). Differentiation of BM-MSCs towards osteogenic
(Alizarin Red staining) and adipogenic (Oil-red O staining) lineages further confirms the identity
of our cell cultures (Figure 1c) [33]. Passages from 9 to 14 have been used since mouse BM-MSCs,
differently from other species (i.e., human and rat), maintain a high contamination of hematopoietic
cells for a longer time in culture [34]. Possible senescence was evaluated by comparing SA-β-Gal
activity in BM-MSC at P6 and P14, representative of early and late passages of the cultures used in
our experiments (Figure 1d). The percentage of β-Gal positive cells was similar in the two passages
(Figure 1e). Furthermore, two other markers of senescence, the phosphorylation of Ser-139 of histone
H2A.X (Figure 1f), indicative of oxidative stress, and the protein level of the cell cycle regulator
p16INK4A (Figure 1g), were investigated by Western blot. Lysates from BM-MSCs at passages ranging
from P5 to P17 were compared with cells treated with H2O2 to induce oxidative stress (positive control),
showing that no significant difference in senescence processes activation was detected in the passages
of BM-MSCs used for our experiments compared to earlier ones.
EVs secreted by BM-MSCs into the cell culture medium were purified by ultracentrifugation
following a widely used protocol yielding a pool of microvesicles and exosomes [26]. Nanoparticle
tracking analysis (NTA) allowed the determination of the size and the concentration of isolated
EVs (Figure 2a). The results of 5 independent preparations show the three most represented vesicle
populations, associated with three peak sizes (two >100 nm, one ~400 nm), indicating the successful
isolation of a pool of EVs, including both exosomes and microvesicles. The mean concentration of the
major vesicle peak (130 nm) was 1.48 × 106 particles/mL (± 88027 SEM) (Figure 2a, left panel). The total
concentration measured as the area under the curve (AUC) of the mean values of all preparations tested
resulted in 1.4 × 109 particles/mL (Figure 2a, right panel). The analysis of EV-depleted supernatants
showed a mean particle concentration of 3.18 × 105 particles/mL (± 26123 SEM) and a major peak
at 94.50 nm (Figure 2a, green line), indicating an efficient yield of the procedure for EVs larger
than 100 nm. The analysis by cryo-electron microscopy performed on EV preparations just after
centrifugation showed the presence of vesicles of different sizes compatible with exosomes and
microvesicles, surrounded by a lipid bilayer and with a variably dense content, confirming furthermore
the integrity and the identity of the vesicles (Figure 2b). A first characterization of EVs’ specific surface
markers was performed by flow cytometry. In particular, CD9 and CD49, even though the latter
was expressed at a lower extent, were detected on BM-MSC-EVs (Figure 2c). The gating strategy
used beads allowing selection of events below 1.34 µm. Using Phalloidin to label cellular debris,
we further gated against contaminating events that could fall within this size. To further ensure that
the analyzed events were within the size range of EVs, we also performed a calibration with Megamix
beads (Biocytex) ranging from 0.1 µm to 0.9 µm using the same acquisition parameters used for
EV analysis, showing that most of the gated events positive for CD9 and CD49 were in the range
between 0.1 and 0.9 µm (Supplementary Figure S1). To support the vesicular origin of CD9 and CD49
events, antibody-stained EVs, following first flow cytometry acquisition, were treated with 0.05% (w/v)
Triton-X100 for 30 min and re-acquired afterwards for the same time, showing a massive reduction of
(CD9+/CD49+) events thereafter (Figure 2d). This supports the vesicular nature of these events [35].
In addition, well-established EV markers, such as Alix, CD9, CD63, HSP70, AGO2 and TSG101,
were identified by Western blots in P14 EV lysates obtained from approximately 1 × 109 particles and
compared to BM-MSC lysates (Figure 2e).
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CD29, CD49 and CD9 (markers also found on EVs). (b) Percentages of surface marker positive 
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Representative images showing differentiation of BM-MSCs into OSTEOCYTES (Alizarin Red 
staining) and ADIPOCYTES (Oil-red O staining) lineages. Controls: untreated BM-MSC cultures 
Figure 1. Characterization of murine Bone Marrow Mesenchymal Stem Cells (BM-MSCs). (a) Representative
panels of flow cytometry analysis showing surface markers of BM-MSCs between passages 6 and 14.
Lineag Hematopoietic Markers (LINEAGE) negative cells (96.4 ± 8.4%) are also negative for CD117
and CD31, excluding contamination by hematopoietic cells; they are strongly positive for SCA1
(stemnes m rker) for CD73 and CD105 (mesenchymal markers) nd for CD44, CD29, CD49 and CD9
(markers also found on EVs). (b) Percentages of surface marker positive populations (mean ± SEM;
flow cytometry experiments of 6 independent BM-MSC cultures). (c) Representative images showing
differentiation of BM-MSCs into OSTEOCYTES (Alizarin Red staining) and ADIPOCYTES (Oil-red O
staining) lineages. Controls: untreated BM-MSC cultures (upper row). Scale bars: 400 µm. (d) β-Gal
assay was performed on BM-MSCs at P6 and P14 to test senescence of cells maintained in culture.
Cells positive for X-gal were quantified and compared to the total population; no significant differences
between the passages were detected (p = 0.3462; statistical analysis was performed by ANOVA test).
Scale bar: 100 µm. (e) Representative images for X-Gal of BM-MSCs at P6 and P14. (f,g) Histone H2A.X
phospho S139 (f) and p16INK4A (g) Western blot analysis, showing that senescence processes are not
differently activated during cell passages in vitro.
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“Total events” gate. BM-MSC-EVs appear in the “Total events” panel. Events falling within the 
“Electronic Noise”, represented in gray, were subtracted from all analysis gates. Bona fide EVs were 
Phalloidin negative (“Phalloidin neg events”) and were shown to be mainly CD9-FITC+, CD49-A647+ 
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Figure 2. Characterization of BM-MSC-derived EVs. (a) Left panel: Nanoparticle Tracking Analysis
(NanoSight NS300) of BM-MSC-EVs isolated by ultracentrifug tion (red) compared to EV-depleted
medium (EVDM) (green). Particle size distribution (left panel) shows that thre populations
corresponding to ~100 nm, ~150 nm, ~400 nm are the most represented on the red plot (arrows),
indicating isolation of different pools of vesicles (> 100 nm exosomes and microvesicles). The green
plot shows that fewer and smaller-sized vesicles (average size = 94.50 nm) remain in the medium after
ultracentrifugation. Right panel: total particle concentration of isolated BM-MSC-EVs (red histogram)
compared to the EVDM (green histogram). All data represent means and standard error of the mean
(SEM) of 5 (BM-MSC-EV) and 4 (EVDM) independent pre arations. (b) is lization of purified
BM-MSC-EVs by cryo-EM: a heterogeneous population of EVs ur o by a lipid bilayer of sizes
compatible with exosomes and microvesicles with a electron-dense core was observed. Note the
integrity of membrane vesicles. Scale bar = 150 nm. (c) Representative panels showing flow cytometry
analysis of EVs from BM-MSCs. Arrows between panels indicate the consecutive gating strategies
for the analysis. The “gate strategy” panel shows the forward (FSC-A) and side (SSC-A) scatter
density profile of 0.79 µm (red dots) and 1.34 µm (green dots) dimensional beads, which were used
to include all events (< 1.34 µm) for specific marker analysis. Smaller events defined as “Electronic
Noise”, falli g below the limit of resolutio of the instrument were also included in the “Total events”
gate. BM-MSC-EVs a pear in the “Total vents” panel. Events falling within th “Electronic Noise”,
represented in gray, were subtracted from all analysis gates. Bona fide EVs were Phalloidin negative
(“Phalloidin neg events”) and were shown to be mainly CD9-FITC+, CD49-A647+ or double positive
(“EV-like events”). (d) Adding 0.05% (w/v) TX-100 for 30 min after acquisition (left panel) resulted in
a major decrease in the CD49+/CD9+ stained population (right panel). (e) EVs and BM-MSC lysates
(5µg) were analyzed by immunoblotting with antibodies against EV proteins Alix, AGO2, HSP70,
TSG101, CD63 and CD9. (f) Left panel: Immunoblotting showing the presence of Neprilysin on EVs
and in BM-MSC lysates (5 µg). Right panel: Real-time PCR analysis of Nep relative expression in P14
BM-MSC RNA normalized to β-actin and to the expression in murine primary fibroblasts.
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Since previous work reported the presence of Neprilysin (NEP), an enzyme able to exert
Aβ-degrading activity, on human ADSC and their exosomes, we also tested NEP expression in
BM-MSCs and their derived EVs. Interestingly, NEP could be detected in the EVs’ lysates and its
mRNA was also expressed in P16 BM-MSCs, at a level more than 100 times that of murine fibroblasts
(Figure 2f).
The earliest signs of cognitive impairments in APP/PS1 mice have been reported in six-month-old
animals [36]. Conversely, amyloid plaque deposition has been shown to start at approximately six
weeks of age in the neocortex and at about three to four months of age in the hippocampus [37,38].
To assess the effects of BM-MSC-EVs in the APP/PS1 AD mice at early stages of the disease, before
the behavioral manifestations become apparent, we performed intraparenchymal injections of EVs
in the cortex of mice at 3 and 5 months of age and evaluated, 25 days later, EV effects on two of the
typical early signs of the disease, Aβ deposition and appearance of dystrophic neurites (Figures 3
and 4). No gross AD-unrelated behavioral alteration was observed in mice treated with EVs compared
to PBS-treated ones. Brain sections from hippocampus and cortex of EV-treated APP/PS1 compared
to mice injected with vehicle (PBS, referred to as the controls) were immunohistochemically stained
with 6E10 antibody, reacting with the N-terminal domain of human Aβ1-42 peptide. The injection of
BM-MSC-EVs in 5-month-old mice (Figure 3) resulted 1 month later (i.e., at 6 months) in a reduction of
Aβ plaque area in both hippocampus and cerebral cortex, depicted by two representative images with
their close-up views on plaques (Figure 3a). Moreover, plaque solidity, a parameter that represents Aβ
loading of plaques, was strongly reduced, in particular within the neocortex (Figure 3b), the region in
which the injection has been performed. In addition, the plaque density (number of plaques/µm2) was
significantly affected by EV treatment in the hippocampal region, but not in the cortex (Figure 3b).
We then performed the same analysis in 4-month-old mice (Figure 4) displaying significantly
smaller and a lower number of plaques relative to the 6-month-old mice (compare the area and density
in the control animals in Figures 3b and 4b). The injection of BM-MSC-EVs was able to decrease the
average plaque area, mostly in the hippocampus, and reduced the density (number of plaques/µm2)
both in the hippocampus and in the cortex when compared to the age-matched controls (Figure 4b).
On the basis of these results, we can hypothesize that EVs may operate not only by promoting the
disaggregation of Aβ pre-existing deposits (Figure 3), but also by preventing or slowing down the
formation of new plaques (Figure 4).
It is known that, in neurons, microtubule disruption and microtubule-based transport impairment,
as well as neurofilament disorganization, lead to dystrophic neurite formation [39,40]. Along with
dysfunction associated with axonal swelling and impaired transport, the axonal dystrophy is likely to
exacerbate downstream neurodegeneration, leading to cognitive deficits. In an attempt to investigate
whether the reduction of Aβ plaques resulted in amelioration of neurite morphology, we analyzed
dystrophic neurites in the cortex and hippocampus of AD mice. Immunostaining of brain sections
25 days following injection of EVs at both ages was performed with Smi31-32 antibodies, which recognize
neurofilament H and M [41] (Figure 5). ThT-positive plaques were surrounded by dystrophic neurites
(Smi31-32-positive) at both ages analyzed, with the results being significantly higher at 6 months
than at 4 months (Figure 5a). Notably, the injection of BM-MSC-EVs reduced the number of Smi31-32
positive dots in the area of the plaques. Although the decrease was evident at both ages, the results
were only statistically significant at 6 months (Figure 5b,c).
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Figure 3. Intracerebral injection of BM-MSC-EVs (MSC-EVs) into 5-month-old APP/PS1 mice reduces 
amyloid deposition after ~1 month. (a) Immunohistochemical staining (DAB) of Aβ1-42 plaques in 
brains of APP/PS1 mice treated with vehicle (CONTROL, top) or MSC-EVs (bottom). Scale bar: 1mm. 
Panels on the right show higher magnification of representative plaques, contoured in the inset. Scale 
bar: 100µm. Cortex (CX) and Hippocampus (HP) are indicated. (b) Quantification of Aβ1-42 positive 
plaques in the Cortex (CX; upper graphs: green and red histograms) and in the Hippocampus (HP; 
lower graphs: orange and blue histograms). Each dot represents an animal for which 10 slices have 
been scored. Statistical analysis was performed by non-parametric Mann-Withney test (* p < 0.05; ** p 
< 0.01). 
Figure 3. Intracerebral injection of BM-MSC-EVs (MSC-EVs) into 5-month-old APP/PS1 mice reduces
amyloid d positio af er ~1 month. (a) Immunohistochemical staining (DAB) of Aβ1-42 plaques in
brains of APP/PS1 mice treated with vehicle (CONTROL, top) or MSC-EVs (bottom). Scale bar: 1 mm.
Panels on the r gh show hig er magnification of re resentative plaques, contoured in the inset.
Scale bar: 100 µm. Cortex (CX) and Hippocampus (HP) are indicated. (b) Quantification of Aβ1-42
positive plaques in the Cortex (CX; u per graphs: green an red histograms) a d in the Hippocampus
(HP; lower g aphs: orange and blue histogr ms). Each dot represents an animal for which 10 slices
have been scored. Statistical analysis was performed by non-p rametric Mann-Withney test (* p < 0.05;
** p < 0 01).
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Figure 4. Intracerebral injection of BM-MSC-EVs (MSC-EVs) into 3-month-old APP/PS1 mice reduces 
amyloid deposition after ~1 month. (a) Immunohistochemical staining (DAB) of Aβ1-42 plaques in 
brains of APP/PS1 mice treated with vehicle (CONTROL, top) or MSC-EVs (bottom). Scale bar: 1mm. 
Panels on the right show higher magnification of representative plaques, contoured in the inset. Scale 
bar: 100µm. Cortex (CX) and Hippocampus (HP) are indicated. (b) Quantification of Aβ1-42 positive 
plaques in the Cortex (CX; upper graphs: light blue and grey histograms) and in the hippocampus 
(HP; lower graphs: violet and brown histograms). Each dot represents an animal for which 10 slices 
have been scored. Statistical analysis was performed by non-parametric Mann-Whitney test (*p < 0.05; 
** p < 0.01). 
It is known that, in neurons, microtubule disruption and microtubule-based transport 
impairment, as well as neurofilament disorganization, lead to dystrophic neurite formation [39,40]. 
Along with dysfunction associated with axonal swelling and impaired transport, the axonal 
dystrophy is likely to exacerbate downstream neurodegeneration, leading to cognitive deficits. In an 
attempt to investigate whether the reduction of Aβ plaques resulted in amelioration of neurite 
Figure 4. Intracerebral injection of BM-MSC-EVs (MSC-EVs) into 3-month-old APP/PS1 mice reduces
amyloid deposition after ~1 month. (a) Immunohistochemical staining (DAB) of Aβ1-42 plaques
in brains of APP/PS1 mice treated with vehicle (CONTROL, top) or MSC-EVs (bottom). Scale bar:
1 mm. Panels on the right show higher magnification of representative plaques, contoured in the
inset. Scale bar: 100 µm. Cortex (CX) and Hippocampus (HP) are indicated. (b) Quantification of
Aβ1-42 positive plaques in the Cortex (CX; upper graphs: light blue and grey histograms) and in the
hippocampus (HP; lower graphs: violet and brown histograms). Each dot represents an animal for
which 10 slices have been scored. Statistical analysis was performed by non-parametric Mann-Whitney
test (*p < 0.05; ** p < 0.01).
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Figure 5. Dysmorphic Neurites around Aβ plaques in APP/PS1 brain cortex slices are reduced 
following MSC-EVs treatment. (a) Left panel: Quantification of Smi31-32 spots (density), representing 
dystrophic neurites, in the 3D reconstructed ROIs acquired around plaques in brain slices of 6- (dark 
grey histogram) and 4-month-old (light grey histogram) control APP/PS1 mice. Smi31-32 signal 
density in 6-month-old APP/PS1 brains is significantly reduced (central panel, white histogram), but 
not at 4 months (right panel). Statistical analysis was performed by non-parametric Mann-Whitney 
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Scale bars: 50 µm. 
4. Discussion  
Figure 5. Dysmorphic Neurites around Aβ plaques in APP/PS1 brain cortex slices are reduced
following MSC-EVs treatment. (a) Left panel: Quantification of Smi31-32 spots (density), representing
dystrophic neurites, in the 3D reconstructed ROIs acquired around plaques in brain slices of 6-
(dark grey histogram) and 4-month-old (light grey histogram) control APP/PS1 mice. Smi31-32 signal
density in 6-month-old APP/PS1 brains is significantly reduced (central panel, white histogram),
but not at 4 months (right panel). Statistical analysis was performed by non-parametric Mann-Whitney
test (* p < 0.05). (b) Representative max projections of confocal images of brain slices of 6-month-old
APP/PS1 mice 25 days following treatment with EVs (MSC-EVs) or with PBS (Control). Immunostaining
with ThT (blue, Aβ plaques) and Smi31-32 (red, dystrophic neurites) are shown. Scale bars: 50 µm.
4. Discussion
MSC-derived EVs are increasingly attracting the attention of the scientific community as possible
therapeutic tools. By promoting neurogenesis, angiogenesis and remodeling of nervous processes and
being endowed with immunomodulatory actions [42–45], MSC-EVs might exert protective roles in
the brain.
In the last few years, the possibility of exploiting the therapeutic potential of EVs has been
evaluated in AD preclinical models, where encouraging outcomes have been achieved [11,46,47].
The studies reported so far, however, have explored the therapeutic potential of MSC-EVs at
a stage in which the pathology is already developed and the cognitive deficits are overt, i.e., a condition
that is difficult to revert. In particular, two different labs have investigated the effects of EVs on AD mice
when the pathology is clearly manifested: Cui and collaborators have shown that 7-month-old APP/PS1
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mice, treated twice a week for 4 months with exosomes extracted from hypoxic MSCs, improved
cognitive impairments compared to untreated AD mice [47]; Wang and coworkers conclude from
their study that MSC-derived EV treatment of AD mice suppress iNOS expression and ameliorates
cognitive behavior by partially rescuing the Aβ-induced deficits in hippocampal synaptic plasticity [48].
We therefore wondered whether carrying out the intervention earlier could lead to positive outcomes,
possibly slowing down AD progression. Even if it is still probably too early to answer this question,
our results could represent a perspective in this direction. In the present study, we assessed the effects
of BM-MSC-EVs in AD mice at a young age when the plaques are just beginning to appear and the
overt cognitive deficits are not yet manifested.
Following extensive characterization of EVs obtained from murine BM-MSCs, we showed
that they are a mixed population mostly composed of exosomes and microvesicles, endowed with
well-established markers and preserving their integrity following purification, as shown by Cryo-EM.
To investigate the actions induced by BM-MSC-derived EV injection, we compared APP/PS1 mice of
3 and 5 months of age bilaterally injected into the cortex with vehicle (PBS, controls) or MSC-EVs.
Our data suggest that EVs may operate not only by promoting the disaggregation of Aβ pre-existing
deposits (5 months => 6 months), but also preventing or slowing down the formation of new ones
(3 months => 4 months). This in turn could account for neuroprotective effects, as suggested by the
reduction of dystrophic neurites in treated mice.
What are the mechanisms involved in MSC-EV effects? We can speculate that on the one hand,
EVs might act directly on the plaques, inducing their disaggregation through an interaction between
EV lipid membranes and Aβ plaques. EVs have been shown to also act as amyloid scavengers
based on Aβ1-42 ability to bind to glycosphingolipids that are extremely abundant in exosomes [20].
This would lead to phagocytosis of Aβ -along with EVs binding to it- by phagocytic cells (i.e., microglial
cells), in line with the hypothesis that MSC-EVs could promote Aβ clearance by a direct binding.
This possibility would be consistent with the decrease in the plaque area, as well as in the amount of
Aβ within plaques (solidity) observed in treated mice.
On the other hand, MSC-EVs have been described to carry the enzymatically active NEP, a type II
membrane-associated metalloendopeptidase involved in the proteolysis of Aβ [19,49]. When added to
N2a line cells, AD-MSC exosomes reduced both extracellular and intracellular Aβ1-42 deposits [19].
Along this line, the presence of NEP in the lysates of both mouse BM-MSC and their derived EVs,
together with the detection of mRNA expression in the cells (surprisingly high when compared to
fibroblasts) suggests that this could be a possible mechanism explaining EV action on Aβ-plaques
in 3- and 5-month-old APP/PS1 mice. In addition, EVs might also act on microglia cells. In fact,
in AD brains microglia clusters around Aβ1-42 deposit and acquire a polarized phenotype with
hypertrophic processes extending towards plaques [50–52]. Microglia are thought to regulate the
degree of amyloid deposition by phagocytosis of amyloid aggregates with a potentially protective
impact on AD progression [53,54]. Therefore, EVs could act by enhancing microglia functionality and
phagocytosis/degradation ability [51].
Furthermore, MSC-EVs have been reported to induce antioxidant effects. De Godoy and colleagues
proposed that MSC-EVs, thanks to their content including antioxidant enzymes and anti-inflammatory
and/or trophic molecules, exert a neuroprotective action. The authors demonstrated that EVs secreted
by MSC contain and carry catalase that endows EVs of reactive oxygen species (ROS) scavenging
activity [55].
It is likely that MSC-EVs operate through pleiotropic mechanisms, involving a combination of the
above processes, including the inhibition of inflammatory responses, regulation of the immune system,
as well as by carrying biologically active molecules, which in turn may act either directly on amyloid
plaques or on microglial cells, which are the main responsible for Aβ phagocytosis in the brain.
To clarify EV mechanisms of action, a deeper characterization of the content of EVs and of
the different types that participate in tissue repair [56,57] is mandatory. To this end, also exploring
novel purification protocols able to recover also the smallest fractions of EVs is urgently needed [58].
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It has been reported that EVs contain, in addition to the above-mentioned lipids, proteins and nucleic
acids (miRNA, mRNA). Among these, miRNAs inside the lumen could be horizontally transferred to
target cells, contributing to the gene expression regulation. For instance, miR-21 overexpression through
engineered EVs has been shown not only to decrease plaque deposition but also to down-regulate the
levels of TNF-α and IL-1β therefore inducing anti-inflammatory effects [47].
In this study, we focused our attention on EV actions on Aβ plaques and dystrophic neurites,
which represent one of the typical hallmarks of AD. We are aware that the correlation between plaque
load and cognitive scores in humans has recently been questioned [59,60], prompting the scientific
community to look for additional factors, beyond the “Amyloid Hypothesis”, as the etiological
mechanism of AD. However, our results represent a clear indication that plaque formation could be
delayed by BM-MSC-EVs and that this may significantly reduce the extent of dystrophic neurites.
Dystrophic neurites forming around plaques have been recently found to evolve toward progressively
more degenerated forms [61], and to promote the accumulation of the amyloid precursor protein (APP)
cleaving enzyme (BACE1), which is required for Aβ generation [39]. Given all these processes lead to
exacerbation of amyloid pathology in AD, the MSC-EVs-mediated reduction of dystrophic neurite
formation may represent an important cue for slowing disease progression.
Moreover, since MSCs have a high immunoregulatory potential and their derived EVs maintain
such ability, next studies will be focused on the analysis of the anti-inflammatory action and how it could
cooperate with Aβ degrading action in AD therapy. Indeed, MSC-EVs can induce anti-inflammatory
effects through the regulation of cytokine release [47,55,62] or iNOS inhibition or by preventing Aβ
oligomer toxicity [48], given that iNOS is a common target of many inflammatory pathways and
an important endpoint for the therapeutic effects of EVs.
Finally, we believe that EVs and their abilities inherited from BM-MSCs could represent
an applicable, safe and cost-effective approach in cell-free regenerative medicine to improve therapy for
preventing the earliest stages of the disease to proceed towards AD. We can venture the hypothesis that
our data could support the use of EVs in patients when the first signs of Mild Cognitive Impairment
begin to appear. Nonetheless, before translating their use into the clinic, a better understanding of EV
actions and their biological functions need to be undertaken, together with the choice of the best route
of administration. In this respect, intranasal administration, being less invasive, easy and cheap could
represent a valid option.
In conclusion, our results highlight that intracortical delivery of bona fide murine BM-MSC-EVs
to APP/PS1 mice at 3 months, before overt clinical signs, is able to prevent Aβ plaque formation and in
5-month-old mice can reduce dystrophic neurons occurrence. As far as we know, this study represents
the first evidence of a possible preventive effect of BM-MSC-EVs in an animal model of AD. This result
can be relevant if we consider that until now clinical trials and treatments adopted for AD therapy did
not produce the desired results, probably because started too late.
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